Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Research
    • Structural Heart Disease
    • TAVR
    • Therapies
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe

Search form

Home
News You Need to Know Today
News Alert: FDA, FTC warn 10 companies for making ‘fraudulent claims’ about unapproved diabetes supplements
Thursday, September 9, 2021
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

News Alert

FDA, FTC warn 10 companies for making ‘fraudulent claims’ about unapproved diabetes supplements

Each company is believed to be in violation of the Federal Food, Drug and Cosmetic Act. They have 15 working days to respond. 

READ MORE >
pills-384846_960_720.jpg
Share on Twitter Share on Facebook Share on Linkedin

FDA, FTC warn 10 companies for making ‘fraudulent claims’ about unapproved diabetes supplements

Share on Twitter Share on Facebook Share on Linkedin
pills-384846_960_720.jpg
Each company is believed to be in violation of the Federal Food, Drug and Cosmetic Act. They have 15 working days to respond. 
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Week in Review: Expanded coverage for AI-based coronary plaque assessments | Compensation climbs | STEMI recommendations
Week in Review: The top children's heart hospitals | Flurpiridaz vs. SPECT | Medtronic's new Class I recall | J&J's big move
Week in Review: FDA approves flurpiridaz | Intermittent fasting good for the heart | Docs accused of negligence | AI for CCTA
September's Top Stories: A historic procedure | Private practice sues hospital | FDA approves radiotracer | TAVR bests SAVR
Week in Review: Tracking Class I recalls | AI IDs hypertension | FTC sues over insulin | LBBAP & TAVR
Week in Review: World's first fully robotic heart transplant | AR & VR in cardiology | IVUS vs. OCT | Much more
Week in Review: Imaging patients with implanted devices | FDA clears AI platform | Cardiologist heads to prison | Much more

Pagination

    • First page « First
    • Previous page ‹ Previous
    • Page 1
    • Current page 2
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9 …
    • Next page Next ›
    • Last page Last »
  • Home
  • News
  • Sitemap
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • AI in Healthcare
  • Cardiovascular Business
  • HealthExec
  • Health Imaging
  • Radiology Business
 
© 2024 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme